VintaBio's development and manufacturing team has over a century of experience in the cell and gene therapy space and its members have played key roles in the development of the most advanced therapies on the market today. VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, a vital and currently underserved area of CGT development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/23 | $64,000,000 | Venture |
Decheng Capital | undisclosed |
